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Conclusion: MBG underestimates MVO after an optimal revascularization
in AMI compared to CMR. This study suggests the superior accuracy of
delayed enhanced magnetic resonance (DEMR) over MBG for the assessment
of myocardial reperfusion injury which is needed in clinical trials where the
principal endpoint is the reduction of infarct size (IS) and MVO. 
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The CYP2C19*2 genetic variant is known to contribute to low responsive-
ness to clopidogrel treatment, leading to a higher rate of cardiovascular events.
Systematic identification of the 2C19*2 carriers to predict the individual
patient’s response to clopidogrel is a matter of debate.
Data of the VASP-02 study comparing patients’ responsiveness to 75 and
150 mg/day maintenance dose of clopidogrel (Aleil et al., J Am Coll Cardiol
Intv 2008) were reanalyzed by determining the 2C19*2 carrier status of the
patients. Platelet reactivity index (PRI) was determined using the VASP
method. A PRI>69 % defines low responsiveness to clopidogrel.
In the 37 non responder patients, 42.4 % were 2C19*2 carriers versus 22.0
% in the responder patients (p=0.022). After multivariate analysis, 2C19*2
polymorphism and high body weight were two independent predictors of high
PRI (odds ratio [95% confidence interval] 3.39 [1.06-10.84] p=0.039 and 3.14
[1.19-8.30] p=0.021) respectively. Increasing the maintenance dose of clopido-
grel from 75 to 150 mg/day in non responder patients resulted in a significant
decrease of PRI from 76.4±4.6 to 62.8±10.4 % (p<0.01) in 2C19*2 carriers
and from 76.1±5.3 to 60.8±13.4 % (p<0.01) in non carriers. The mean
decrease of PRI after doubling the dose was not significantly different between
carriers and non carriers of the genetic variant (-13.6±9.3 and -15.3±11.8 %
p=0.39, respectively).
CYP2C19*2 is an important determinant of the responsiveness to clopido-
grel while other independent factors such as body weight also are involved.
Hyporesponsiveness in 2C19*2 carriers can be easily overcome by doubling
the maintenance dose of clopidogrel. Thus, combined functional pharmacody-
namic monitoring and genetic determination of CYP profile should help
improve patient’s responsiveness to clopidogrel.
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Introduction: Numerous biological studies have reported inter-individual
variability in platelet response to clopidogrel with clinical relevance. High
Post treatment platelet reactivity (ADP-induced aggregation >70%) has been
proposed to define Non response to clopidogrel. We assessed in clopidogrel
non responders undergoing elective percutaneous coronary intervention (PCI)
the benefit of adjusted antiplatelet therapy with glycoprotein IIbIIIa (GPII-
bIIIa) antagonist administration during PCI for one month clinical outcome.
Methods and Results: 149 clopidogrel non-responders referred for elec-
tive PCI were prospectively included and randomized to “conventional group”
(n=75) or “active group” with GPIIbIIIa antagonist (n=74). All patients
received 250 mg aspirin and 600 mg clopidogrel before PCI and platelet tes-
ting. The rate of CV events at one month was significantly lower in the “active
group” than in the “conventional group”: 19% (n=14) vs. 40% (n=30),
p=0.006, [OR (95%CI): 2.8(1.4-6.0)]. No patient in either group had post pro-
cedural TIMI major bleeding or required transfusions.
Conclusion: The present study suggested benefit of tailored antiplatelet
therapy during elective PCI with GPIIbIIIa antagonist for clopidogrel non res-
ponders without increased bleeding risk.
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Objectives: To determine if the speed of response to clopidogrel loading
predicts the final degree of response to clopidogrel.
Background: Fast inhibition of platelet aggregation is important in the set-
ting of ACS and PCI, but its relation to the final degree of inhibition is not
well established.
Methods: We performed a post-hoc analysis of ALBION, which included 103
NSTE-ACS patients randomised to 300, 600 or 900mg LD of clopidogrel. Early
kinetic profiles of ADP 20μmol/l Maximal Platelet Aggregation (MPA) and del-
taMPA (with baseline sample as reference) were studied, with 8 time points within
the 24 hours following loading. Low response was defined as deltaMPA<10%
p=0.006
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